Showing 2971-2980 of 5771 results for "".
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin
- NextGen Healthcare Launches AI-Powered Ambient Listening Solution for Ophthalmologists and Optometristshttps://modernod.com/news/nextgen-healthcare-launches-ai-powered-ambient-listening-solution-for-ophthalmologists-and-optometrists/2482472/NextGen Healthcare has announced the availability of its AI-driven ambient listening solution, NextGen Ambient Assist, for ophthalmologists and optometrists. This technology aims to streamline clinical workflows and significantly reduce documentation burdens, saving medical professionals up
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi
- Aldeyra Resubmits NDA for Topical Ocular Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-resubmits-nda-for-topical-ocular-reproxalap-for-dry-eye-disease/2482469/Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for its investigational topical drug, reproxalap, which is intended to treat the signs and symptoms of dry eye disease. The resubmission follows a recent FDA-requested trial that demonst
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens
- MaximEyes.com Ophthalmology EHR Integrates with AAO IRIS Registryhttps://modernod.com/news/maximeyescom-ophthalmology-ehr-integrates-with-aao-iris-registry/2482464/MaximEyes.com, a cloud-based electronic health records (EHR) platform tailored specifically for ophthalmology and optometry practices, announced its integration with the American Academy of Ophthalmology (AAO) IRIS Registry (Intelligent Research in Sight). This integration will allow ophthal
- Ocuphire Publishes Phase 3 Trial Results of Ryzumvi for Reversal of Pharmacologically-Induced Mydriasishttps://modernod.com/news/ocuphire-publishes-phase-3-trial-results-of-ryzumvi-for-pharmacologically-induced-mydriasis-1/2482463/Ocuphire Pharma announced the full results from two pivotal phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of Ryzumvi (phentolamine ophthalmic solution 0.75%) for reversing pharmacologically-induced mydriasis. The data were
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- Eyenovia Launches Clobetasol for Postoperative Ocular Surgery Pain and Inflammationhttps://modernod.com/news/eyenovia-launches-clobetasol-for-postoperative-ocular-surgery-pain-and-inflammation/2482460/Eyenovia announced the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, which is designed to address postoperative inflammation and pain following ocular surgeries. The FDA approval and launch marks the first new ophthalmic steroid to be a